Ibd CAncer and seRious infections in Europe - I-CARE

Hoptial Lariboisière- Service de Gastroenterologie0 个研究点目标入组 13,262 人开始时间: 2016年2月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patient with an established diagnosis of Crohn´s disease, ulcerative colits or IBD, unclassified made at least 3 months earlier based on usal radiological, endoscopic or histological criteria.
•Patient 18 an older accepting to sign the informed participating consent form, stating that he accepts to provide personal details to complete the electronic studydocumentation as required and to be contacted by a Study Coordinator and his gastroenterologist for the purpose of the study during the entire study period if required.

•Patient unable to sign the informed consent form.
•Patient with no regular access to internet.
•Treatment at entry in the study with an immunomodulator different from thiopurines and methotrexate.
•At the time of inclusion in the study, therapy was not assigned to any of the groups mentioned.
•Patient previously enrolled in a randomized clinical trial.

发起方

Hoptial Lariboisière- Service de Gastroenterologie